Literature DB >> 9765287

Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth.

J A Harrop1, P C McDonnell, M Brigham-Burke, S D Lyn, J Minton, K B Tan, K Dede, J Spampanato, C Silverman, P Hensley, R DiPrinzio, J G Emery, K Deen, C Eichman, M Chabot-Fletcher, A Truneh, P R Young.   

Abstract

Herpesvirus entry mediator (HVEM), a member of the tumor necrosis factor (TNF) receptor family, mediates herpesvirus entry into cells during infection. Upon overexpression, HVEM activates NF-kappaB and AP-1 through a TNF receptor-associated factor (TRAF)-mediated mechanism. Using an HVEM-Fc fusion protein, we screened soluble forms of novel TNF-related proteins derived from an expressed sequence tag data base. One of these, which we designated HVEM-L, specifically bound to HVEM-Fc with an affinity of 44 nM. This association was confirmed with soluble and membrane forms of both receptor and ligand. HVEM-L mRNA is expressed in spleen, lymph nodes, macrophages, and T cells and encodes a 240-amino acid protein. A soluble, secreted form of the protein stimulates proliferation of T lymphocytes during allogeneic responses, inhibits HT-29 cell growth, and weakly stimulates NF-kappaB-dependent transcription.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9765287     DOI: 10.1074/jbc.273.42.27548

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  68 in total

Review 1.  Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors.

Authors:  B G Darnay; B B Aggarwal
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Localization of the gD-binding region of the human herpes simplex virus receptor, HveA.

Authors:  J C Whitbeck; S A Connolly; S H Willis; W Hou; C Krummenacher; M Ponce de Leon; H Lou; I Baribaud; R J Eisenberg; G H Cohen
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

3.  Turning on LIGHT.

Authors:  S W Granger; C F Ware
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

4.  Differential expression of LIGHT and its receptors in human placental villi and amniochorion membranes.

Authors:  Ryan M Gill; Jian Ni; Joan S Hunt
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

5.  The protein kinase PKR: a molecular clock that sequentially activates survival and death programs.

Authors:  Olivier Donzé; Jing Deng; Joseph Curran; Robert Sladek; Didier Picard; Nahum Sonenberg
Journal:  EMBO J       Date:  2004-01-29       Impact factor: 11.598

Review 6.  The role of LIGHT in T cell-mediated immunity.

Authors:  Jing Wang; Yang-Xin Fu
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

7.  Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells.

Authors:  Isabell Lang; Simone Füllsack; Agnes Wyzgol; Andrea Fick; Johannes Trebing; José Antonio Carmona Arana; Viktoria Schäfer; Daniela Weisenberger; Harald Wajant
Journal:  J Biol Chem       Date:  2015-12-31       Impact factor: 5.157

Review 8.  TNF superfamily: costimulation and clinical applications.

Authors:  Dass S Vinay; Byoung S Kwon
Journal:  Cell Biol Int       Date:  2009-02-20       Impact factor: 3.612

9.  TRAF2 plays a key, nonredundant role in LIGHT-lymphotoxin beta receptor signaling.

Authors:  You-Sun Kim; Sergei A Nedospasov; Zheng-Gang Liu
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

10.  Fas ligand-induced murine pulmonary inflammation is reduced by a stable decoy receptor 3 analogue.

Authors:  Mark A Wortinger; Joseph W Foley; Patrick Larocque; Derrick R Witcher; Michael Lahn; Joseph A Jakubowski; Andrew Glasebrook; Ho Yeong Song
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.